ATTRiumph study

Recruiting
99 years or below
All
Phase N/A
10 participants needed
1 Location

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with ATTR-CM who are treated with standard-of-care therapy as determined by the treating and study physician(s).
The study duration will be up to 77 weeks, comprising: A 5-week Screening Period (may be extended up to 60 days in some circumstances) A 52-week Treatment Period
A 16-week Safety Follow-up Period
The site visit frequency during the Treatment Period will be approximately every 1 to 2 weeks until Week 4 (Visit 4) and approximately every 4 weeks thereafter, with off-site visits approximately every 2 weeks in between the on-site visits

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 30 Jun 2026. Study ID: 26-6915

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center